Over the past two decades, ketamine has emerged as a novel effective and rapid-acting
antidepressant. While the vast majority of studies on ketamine have focused on its ability to …

Borderline personality disorder (BPD) has high rates of comorbidity with mood disorders,
including treatment-resistant depression (TRD). Comorbidity of BPD with depression is …

Suicide accounts for approximately 800,000 deaths per year globally. Previous research has
shown that intranasal esketamine and intravenous ketamine can rapidly decrease the …

Background In recent years, ketamine and esketamine treatment have demonstrated rapid
antidepressant effects in adults with treatment-resistant depression (TRD). Hitherto …

BACKGROUND: Mood disorders are a leading cause of morbidity. Many patients
experience treatment-resistant depression (TRD), and suicide rates are rising. Faster-acting …

Introduction The large percentage of adults with major depressive disorder (MDD)
insufficiently responding and/or tolerating conventional monoamine-based antidepressants …

Ketamine is a NMDA receptor antagonist that has a rapid acting antidepressant effect with
high efficacy in treatment-resistant patients. Ketamine is a beneficial antidepressant for …

Background Anhedonia is a trans-diagnostic, multidimensional phenotype that mediates
patient outcomes and suicidality. Convergent evidence suggests that ketamine may be …

Purpose Bipolar disorder is a chronic and recurrent condition often associated with
treatment resistance and suicidality. There is an unmet need for effective treatment in this …

Substance-related disorders are complex psychiatric disorders that are characterized by
continued consumption in spite of harmful consequences. Addiction affects various brain …